BioSpace News Archive

Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced that Zoe Silver has joined the company as Senior Vice President of Genomics & Diagnostics.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference that will be held September 12th – 14th.

The global prurigo nodularis treatment market is anticipated to gather pace in its growth due to the rarity of the disease.

The global breast cancer diagnostics market was valued at US$ 4.8 Bn in 2018 and is projected to expand at a high CAGR from 2019 to 2027.

Human insulin is the name which describes synthetic insulin which is laboratory grown to mimic the insulin in humans.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.

Nearly 20.8 million people across the U.S. are affected with diabetes and 90% of these have type 2 diabetes, which can be termed as insulin deficiency syndrome, wherein type 2 diabetes your body does not use insulin properly.

Allermi announced today that its direct-to-patient telehealth service to provide customized multi-ingredient nasal sprays for the relief of allergy symptoms is now available.

Novarad Corporation announces a strategic alliance with a network of well-established specialty Neurosurgical and Spine distribution partners within the US.

Agilent Technologies Inc. announced that the company has been named a “Best Workplace in Health Care” in the United States by Fortune magazine.